GTC to regain US rights to ATryn from Lundbeck
This article was originally published in Scrip
Executive Summary
GTC Biotherapeutics is to regain US commercialisation rights to ATryn (antithrombin [recombinant]) from Lundbeck to enable both companies to meet "their respective strategic objectives", said GTC.